Results 21 to 30 of about 13,840,459 (217)

Modelling the Genetic Risk in Age-Related Macular Degeneration [PDF]

, 2012
Late-stage age-related macular degeneration (AMD) is a common sight-threatening disease of the central retina affecting approximately 1 in 30 Caucasians.
Weber, Bernhard H. F., Lars G. Fritsche, Weber, Bernhard H.F., Bernhard H. F. Weber, Grassmann, F., Iris M Heid, Grassmann, Felix, Lars G Fritsche, Fritsche Lars G., Keilhauer Claudia N., Keilhauer, Claudia N., Claudia N. Keilhauer, Claudia N. Keilhauer (162279), Heid, I.M., Heid, Iris M., Felix Grassmann, Felix Grassmann (162264), Fritsche, Lars G., Keilhauer, C.N., Claudia N Keilhauer, Iris M. Heid, Weber, B.H.F., Bernhard H F Weber, Grassmann Felix, Lars G. Fritsche (162272), Fritsche, L.G., Bernhard H. F. Weber (162289), Heid Iris M., Weber Bernhard H. F., Iris M. Heid (87553)   +29 more
core   +1 more source

Prevalence of age-related macular degeneration in Nakuru, Kenya: a cross-sectional population-based study. [PDF]

, 2013
BACKGROUND: Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently been recognised as the leading or second leading cause of blindness in several African countries.
Peto, Tunde; id_orcid, Bastawrous, Andrew, Andrew Bastawrous, Foster, Allen, Kuper Hannah, Allen Foster, Tunde Peto, Hannah Kuper, Tunde Peto (295260), Leung Irene, Irene Leung (336330), Leung, Irene, Wanjiku Mathenge (336328), Bastawrous Andrew, Andrew Bastawrous (336329), Peto Tunde, Hannah Kuper (25751), Wanjiku Mathenge, Allen Foster (94749), Peto, Tunde, Kuper, Hannah, Mathenge Wanjiku, Irene Leung, Mathenge, Wanjiku, Foster Allen   +24 more
core   +1 more source

THE CORRELATION BETWEEN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

, 2021
Purpose: The aim of the current study was to investigate the correlation between the pretreatment aqueous level of vascular endothelial growth factor (VEGF) and clinical activity in neovascular age-related macular degeneration.Methods: Patients with ...
0000-0001-9645-3837, 10749021, 7444, SAISHIN, Yoshitsugu, 大路, 正人, SAWADA, Tomoko, OHJI, Masahito, 澤田, 修, 2767, 2502, 00378465, SAWADA, Osamu, 6625, 一山, 悠介, 90252650, 80531516, 30379193, 澤田, 智子, 7692, 西信, 良嗣, ICHIYAMA, Yusuke, 7250, 90814848, 3728, 0000-0002-9134-9886, 柿木, 雅志, 小幡, 峻平, 0000-0001-9752-0499, OBATA, Shumpei, 伊藤, 友香, 0000-0002-9828-4288, 2737, 0000-0001-6120-2392, ITO, Yuka, KAKINOKI, Masashi   +34 more
core   +1 more source

FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice

Cell Reports, 2017
Pathological neovascularization, a leading cause of blindness, is seen in retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration.
Zhongjie Fu, Yan Gong, Raffael Liegl, Zhongxiao Wang, Chi-Hsiu Liu, Steven S. Meng, Samuel B. Burnim, Nicholas J. Saba, Thomas W. Fredrick, Peyton C. Morss, Ann Hellstrom, Saswata Talukdar, Lois E.H. Smith   +12 more
doaj   +1 more source

The chronic care for age-related macular degeneration study (CHARMED): Study protocol for a randomized controlled trial

Trials, 2011
Background Neovascular age-related macular degeneration is the leading cause of irreversible blindness in people 50 years of age or older in the developed world.
Held Ulrike, Wang Mathyas, Woitzek Katja, Frei Anja, Rosemann Thomas   +4 more
doaj   +1 more source

The estimated prevalence and incidence of late stage age related macular degeneration in the UK [PDF]

, 2012
BACKGROUND: UK estimates of age related macular degeneration (AMD) occurrence vary. AIMS: To estimate prevalence, number and incidence of AMD by type in the UK population aged ≥50 years.
Fletcher, AE, Owen, CG, Rudnicka, AR, Fletcher, Astrid E, Rudnicka, Alicja R, Jarrar, Z, Cook, DG, Wormald, Richard, Wormald, R, Owen, Christopher G, Jarrar, Zakariya, Cook, Derek G   +11 more
core   +1 more source

Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials [PDF]

, 2009
Neovascular age-related macular degeneration (AMD) has a poor prognosis if left untreated, frequently resulting in legal blindness. Ranibizumab is approved for treating neovascular AMD.
Mitchell, P., Holz, F. G., Schmidt-Erfurth, U., Korobelnik, J.-F., Korobelnik, Jean-François, Prunte, Christian, Tano, Yasuo, Schmidt-Erfurth, Ursula Margarethe, Tano, Y., Mitchell, Paul, Wolf, S., Lanzetta, P., Lanzetta, P, Holz, Frank G, Prünte, C., Wolf, Sebastian, F G Holz, J-F Korobelnik, S Wolf, P Mitchell, Y Tano, C Prunte, U Schmidt-Erfurth, P Lanzetta   +23 more
core   +1 more source

Ranibizumab in neovascular age-related macular degeneration

Clinical Interventions in Aging, 2006
Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF).
T Eng, Kenneth, Peter J, Kertes
openaire   +2 more sources

Aflibercept for neovascular age-related macular degeneration

Cochrane Database of Systematic Reviews, 2016
Central vision loss caused by age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. Neovascular AMD is characterized by choroidal neovascularization (CNV). Growth of new blood vessels in patients with neovascular AMD is driven by a complex process that involves a signal protein called ...
Salman, Sarwar, Elizabeth, Clearfield, Mohamed Kamel, Soliman, Mohammad Ali, Sadiq, Andrew J, Baldwin, Mostafa, Hanout, Aniruddha, Agarwal, Yasir J, Sepah, Diana V, Do, Quan Dong, Nguyen   +9 more
openaire   +3 more sources

Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration - the potential sources and molecular cues for their recruitment and activation

EBioMedicine, 2018
Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly in developed countries. Neovascular AMD (nAMD) accounts for 90% of AMD-related vision loss.
Karis Little, Jacey H. Ma, Nan Yang, Mei Chen, Heping Xu   +4 more
doaj   +1 more source